The European Renal Association – European Dialysis and Transplant Association are two of the fastest growing Medical Associations whose purpose are to encourage and to report advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects. A wide variety of lectures and symposia covering the various aspects of basic and clinical nephrology as well as the most recent researches in the field, the ERA-EDTA congress is Europe’s most significant nephrology meeting.

BioPorto will be present at the ERA-EDTA Congress promoting The NGAL Test™. Meet Klaus Boberg Pedersen, Product Manager (kbp@bioporto.com) and Jakob Ohm Eriksen, Product Manager (joe@bioporto.com) at our booth no. 1.G.21.

What is NGAL?

NGAL is a biomarker for diagnosing acute kidney injury (AKI). The biomarker has been recognised by the market as a new way to identify patients at risk of developing potentially severe acute kidney injury (AKI).

To learn more about the ERA EDTA congress please visit: http://eraedta2012.org/